Challenges of biological monitoring in a hemophilia A patient without inhibitors on emicizumab undergoing major orthopedic surgery: a case report
Open Access
- 1 January 2021
- journal article
- case report
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 12
Abstract
A man with severe hemophilia A (HA) without factor VIII (FVIII) inhibitors was admitted for total arthroplasty of his elbow. The patient was being treated with emicizumab, with his last administration given 8 days before surgery. Preoperatively, he received a bolus of 4000 international units (IU) of recombinant (r)FVIII. Throughout the operation, a continuous infusion of 4 IU/kg/h was administered and maintained over 24 hours. On the first postoperative day, the FVIII infusion rate was reduced to 225 IU/h for 4 days and stopped on the fifth day. Under this treatment, no bleeding complications occurred. Emicizumab is known to interfere with a wide range of coagulation assays, thereby challenging replacement therapy monitoring before, during, and after surgery. In this case study, we report on the assessment of FVIII levels at different time points using various reagents. We conclude that for both hematologists and non-hematology clinicians, it is crucial to be aware of emicizumab interferences with routine coagulation tests so as to avoid misinterpretation. In addition, laboratory specialists must be familiar with this treatment in order to select appropriate coagulation tests and provide rapid and reliable result interpretations.Keywords
This publication has 14 references indexed in Scilit:
- A hemophilia A mouse model for the in vivo assessment of emicizumab functionBlood, 2020
- Non‐additive effect on thrombin generation when a plasma‐derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitroJournal of Thrombosis and Haemostasis, 2020
- Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guidelineHaemophilia, 2019
- Emicizumab and thrombosis: The story so farJournal of Thrombosis and Haemostasis, 2019
- Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra®): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP)Haemophilia, 2019
- Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia AThrombosis and Haemostasis, 2019
- Emicizumab use in major orthopedic surgeryBlood Advances, 2019
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without InhibitorsNew England Journal of Medicine, 2018
- Erratum to: Fluid signal changes around the knee on MRI are associated with increased volumes of subcutaneous fat: a case-control studyBMC Musculoskeletal Disorders, 2017
- Low-dose continuous infusion of factor VIII in patients with haemophilia A2015